News & Events about Seagen Inc.
Business Wire
5 months ago
Seagen Inc. (NASDAQ: SGEN) today announced an update to the U.S. Prescribing Information (PI) for ADCETRIS (brentuximab vedotin) to include six-year overall survival results from the phase 3 ECHELON-1 clinical trial of ADCETRIS plus combination chemotherapy in patients with previously untreated...
Avoro Capital Advisors LLC lifted its stake in shares of Seagen Inc. (NASDAQ:SGEN Get Rating) by 1.1% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 1,885,000 shares of the biotechnology companys stock after purchasing an additional 20,000 shares during ...
Business Wire
5 months ago
Seagen Inc. (NASDAQ: SGEN) today announced updated efficacy and safety results from Part C of a phase 2 single-arm trial (SGN35-027) evaluating the antibody-drug conjugate ADCETRIS (brentuximab vedotin) in combination with the PD-1 inhibitor nivolumab and standard chemotherapy agents doxorubicin...
Globe Newswire
7 months ago
NEW YORK, May 02, 2023 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders. Moore Kuehn may seek increased ...
Seagen Inc. (NASDAQ:SGEN Get Rating) SVB Leerink increased their FY2024 earnings per share estimates for Seagen in a research report issued to clients and investors on Tuesday, April 25th. SVB Leerink analyst A. Berens now anticipates that the biotechnology company will post earnings of $0.34 per ...